Previous 10 | Next 10 |
Regular dividend to remain primary capital allocation priority For full year 2023, the company expects revenue and Adjusted EBITDA margin to be within the ranges provided on November 2, 2023 For full year 2023 the company expects free cash flow before one-time spin-related costs to ...
2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...
2024-01-03 08:10:00 ET Summary Organon, a pharmaceutical company, has a diverse portfolio of products in women's health and biosimilars. The company has faced challenges in its women's health segment but expects a turnaround in its top-selling drug and growth in the fertility busi...
2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...
Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2024, at 1:30 p.m. PT. Investors, analys...
2023-12-21 01:08:28 ET Summary Pfizer stock has fallen 45% YTD as it has been impacted by the decline in revenue from COVID-19 products. The recent news about Danuglipron has added fuel to the fire. But is everything so bad when it comes to investing in the company for the long te...
2023-12-20 23:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-19 10:22:30 ET Summary Organon's stock has declined 32% since September, making it one of the worst performers in healthcare. The company reported mixed financial results, with 1% growth in product sales and a decline in total revenue. Organon's biggest challenge is de...
Organon becomes the sole distributor and promoter of Emgality ® ( galcanezumab) and RAYVOW ™ (lasmiditan) in Europe, building on strong commercial expertise in central nervous system disorders Expands Organon’s European product portfolio in a...
2023-12-15 09:45:07 ET United States Steel Corp. (X) X is trading UP for the last 5 days, and it at trading at $39.20 with volume of 3,114,701 and a one day change of $0.34 (0.86%). United States Steel Corp. has a 52-week low of 20.68 and a 52-week high of $35.03. The business's 50-...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 31, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce a new significant gold-silver discovery, called the Navidad vein system, on the Ermitaño Mine concessions in Sonora, Mexico where the Company holds a...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...